(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 161.42% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.91%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Nyxoah Sa's revenue in 2025 is $4,903,370.On average, 4 Wall Street analysts forecast NYXH's revenue for 2025 to be $361,809,371, with the lowest NYXH revenue forecast at $210,341,229, and the highest NYXH revenue forecast at $510,133,622. On average, 4 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,474,447,105, with the lowest NYXH revenue forecast at $1,250,070,651, and the highest NYXH revenue forecast at $1,926,007,057.
In 2027, NYXH is forecast to generate $3,555,403,039 in revenue, with the lowest revenue forecast at $3,183,563,161 and the highest revenue forecast at $3,927,242,916.